Abstract
Immune thrombocytopenia (ITP) is a chronic disease resulting from increased platelet destruction and impaired platelet production. Secondary ITP can be a manifestation of chronic graft-versus-host disease (GVHD) and represent a lymphoproliferative disorder. A boy with chronic graft-versus-host disease after cord blood stem cell transplantation who had severe refractory immune-mediated thrombocytopenia received infusion of rituximab weekly, 375 mg/m2, for 4 weeks. Platelets count of the patient was recovered, and rituximab was well tolerated with no severe toxicity observed during treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med, 2002, 346: 995–1008.
Shu WX, Chen Y. The characteristics of immunophenotype in acute lymphoblastic leukemia and its clinical significance. Chinese-German J Clin Oncol, 2005, 4: 354–357.
McMillan R, Nugent D. The effect of antiplatelet autoantibodies on megakaryocytopoiesis. Int J Hematol, 2005, 81: 94–99.
George JN. Definition, diagnosis and treatment of immune thrombocytopenic purpura. Haematologica, 2009, 94: 759–762.
Newton JL, Reese JA, Watson SI, et al. Fatigue in adult patients with primary immune thrombocytopenia. Eur J Haematol, 2011, 86: 420–429.
Dominietto A, Raiola AM, van Lint MT, et al. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infec tions and cell dose. Br J Haematol, 2001, 112: 219–227.
Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med, 2007, 146: 25–33.
Jillella AP, Kallab AM, Kutlar A. Autoimmune thrombocytopenia following autologous hematopoietic cell transplantation: review of literature and treatment options. Bone Marrow Transplant, 2000, 26: 925–927.
Deng L, Wu BY, Li YH, et al. Immune thrombocytopenia purpura after HLA-haploidentical hematopoietic stem cell transplantation: a case report. Chin J Hematol (Chinese), 2004, 25: 481.
Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med, 2000, 133: 275–279.
Stasi R, Pagano A, Stipa E, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood, 2001, 98: 952–957.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, M., Wang, J., Zhang, Y. et al. Treatment of immune thrombocytopenia after allogeneic cord blood stem cell transplantation with rituximab: a case report. Chin. -Ger. J. Clin. Oncol. 12, 300–302 (2013). https://doi.org/10.1007/s10330-013-1165-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-013-1165-3